Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Improvement of the novel inhibitor for Mycobacterium enoyl-acyl carrier protein reductase (InhA): a structure–activity relationship study of KES4 assisted by in silico structure-based drug screening


InhA or enoyl-acyl carrier protein reductase of Mycobacterium tuberculosis (mtInhA), which controls mycobacterial cell wall construction, has been targeted in the development of antituberculosis drugs. Previously, our in silico structure-based drug screening study identified a novel class of compounds (designated KES4), which is capable of inhibiting the enzymatic activity of mtInhA, as well as mycobacterial growth. The compounds are composed of four ring structures (A–D), and the MD simulation predicted specific interactions with mtInhA of the D-ring and methylene group between the B-ring and C-ring; however, there is still room for improvement in the A-ring structure. In this study, a structure–activity relationship study of the A-ring was attempted with the assistance of in silico docking simulations. In brief, the virtual chemical library of A-ring-modified KES4 was constructed and subjected to in silico docking simulation against mtInhA using the GOLD program. Among the selected candidates, we achieved synthesis of seven compounds, and the bioactivities (effects on InhA activity and mycobacterial growth and cytotoxicity) of the synthesized molecules were evaluated. Among the compounds tested, two candidates (compounds 3d and 3f) exhibited superior properties as mtInhA-targeted anti-infectives for mycobacteria than the lead compound KES4.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6


  1. 1.

    Dye C, Williams BG. The population dynamics and control of tuberculosis. Science. 2010;328:856–61.

    CAS  Article  Google Scholar 

  2. 2.

    Das P, Horton R. Tuberculosis-time to accelerate progress. Lancet. 2010;375:1755–7.

    Article  Google Scholar 

  3. 3.

    Das P, Horton R. Tuberculosis-getting to zero. Lancet. 2015;386:2231–2.

    Article  Google Scholar 

  4. 4.

    Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet. 2010;375:1814–29.

    Article  Google Scholar 

  5. 5.

    Sotgiu G, Centis R, D’Ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med. 2015;5:a017822.

    Article  Google Scholar 

  6. 6.

    Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, et al. InhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 1994;263:227–30.

    CAS  Article  Google Scholar 

  7. 7.

    Parikh SL, Xiao G, Tonge PJ. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry. 2000;39:7645–50.

    CAS  Article  Google Scholar 

  8. 8.

    McMurry LM, McDermott PF, Levy SB. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob Agents Chemother. 1999;43:711–3.

    CAS  Article  Google Scholar 

  9. 9.

    Quemard A, Sacchettini JC, Dessen A, Vilcheze C, Bittman R, Jacobs WR Jr, et al. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry. 1995;34:8235–41.

    CAS  Article  Google Scholar 

  10. 10.

    Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem. 1995;64:29–63.

    CAS  Article  Google Scholar 

  11. 11.

    Tonge PJ, Kisker C, Slayden RA. Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosis. Curr Top Med Chem. 2007;7:489–98.

    CAS  Article  Google Scholar 

  12. 12.

    Rotta M, Pissinate K, Villela AD, Back DF, Timmers LF, et al. Piperazine derivatives: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies. Eur J Med Chem. 2015;90:36–447.

    Article  Google Scholar 

  13. 13.

    Vilcheze C, Morbidoni HR, Weisbrod TR, Iwamoto H, Kuo M, et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol. 2000;182:59–4067.

    Article  Google Scholar 

  14. 14.

    Oliveira JS, Pereira JH, Canduri F, Rodrigues NC, de Souza ON, de Azevedo WF Jr, et al. Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis. J Mol Biol. 2006;359:646–66.

    CAS  Article  Google Scholar 

  15. 15.

    Taira J, Ito T, Nakatani H, Umei T, Baba H, Kawashima S, et al. In silico structure-based drug screening of novel antimycobacterial pharmacophores by DOCK-GOLD tandem screening. Int J Mycobacteriol. 2017;6:142–8.

    CAS  Article  Google Scholar 

  16. 16.

    Taira J, Morita K, Kawashima S, Umei T, Baba H, Maruoka T, et al. Identification of a novel class of small compounds with anti-tuberculosis activity by in silico structure-based drug screening. J Antibiot. 2017;70:1057–64.

    CAS  Article  Google Scholar 

  17. 17.

    Kinjo T, Koseki Y, Kobayashi M, Yamada A, Morita K, Yamaguchi K, et al. Identification of compounds with potential antibacterial activity against Mycobacterium through structure-based drug screening. J Chem Inf Model. 2013;53:1200–12.

    CAS  Article  Google Scholar 

  18. 18.

    Koseki Y, Kinjo T, Kobayashi M, Aoki S. Identification of novel antimycobacterial chemical agents through the in silico multi-conformational structure-based drug screening of a large-scale chemical library. Eur J Med Chem. 2013;60:333–39.

    CAS  Article  Google Scholar 

  19. 19.

    Kanetaka H, Koseki Y, Taira J, Umei T, Komatsu H, Sakamoto H, et al. Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach. Eur J Med Chem. 2015;94:378–85.

    CAS  Article  Google Scholar 

  20. 20.

    He X, Alian A, Stroud R, Ortiz, de Montellano PR. Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosis. J Med Chem. 2006;49:6308–23.

    CAS  Article  Google Scholar 

  21. 21.

    Kobayashi M, Kinjo T, Koseki Y, Bourne CR, Barrow WW, Aoki S. Identification of novel potential antibiotics against Staphylococcus using structure-based drug screening targeting dihydrofolate reductase. J Chem Inf Model. 2014;54:1242–53.

    CAS  Article  Google Scholar 

  22. 22.

    Koseki Y, Aoki S. Computational medicinal chemistry for rational drug design: Identification of novel chemical structures with potential anti-tuberculosis activity. Curr Top Med Chem. 2014;14:176–88.

    CAS  Article  Google Scholar 

  23. 23.

    Schmidt CW. TOX 21: new dimensions of toxicity testing. Environ Health Perspect. 2009;117:A348.

    Article  Google Scholar 

  24. 24.

    Faulon JL, Visco DP, Pophale RS. The signature molecular descriptor. 1. Using extended valence sequences in QSAR and QSPR studies. J Chem Info Comput Sci. 2003;43:707–20.

    CAS  Article  Google Scholar 

  25. 25.

    Berenger F. MolEnc: a molecular encoder using rdkit and OCaml. 2019. Accessed 19 Nov 2019.

  26. 26.

    Breiman L. Bagging predictors. Mach Learn. 1996;24:123–40.

    Google Scholar 

  27. 27.

    Platt J. Probabilistic outputs for support vector machines and comparisons to regularized likelihood methods. Adv Large Margin Classif. 1999;10:61–74.

    Google Scholar 

  28. 28.

    Molle V, Gulten G, Vilcheze C, Veyron-Churlet R, Zanella-Cleon I, Sacchettini JC, et al. Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis. Mol Microbiol. 2010;78:1591–605.

    CAS  Article  Google Scholar 

  29. 29.

    Delaine T, Bernardes-Génisson V, Quémard A, Constant P, Meunier B, et al. Development of isoniazide NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents. Eur J Med Chem. 2010;45:4554–61.

    CAS  Article  Google Scholar 

  30. 30.

    Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol. 1995;245:43–53.

    CAS  Article  Google Scholar 

  31. 31.

    Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol. 1997;267:727–48.

    CAS  Article  Google Scholar 

Download references


This work was supported in part by a Takeda Science Foundation to JT, and a Grant-in-Aid for Scientific Research (C) (26460145) to SA and (18K05358) to HS from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Author information



Corresponding author

Correspondence to Shunsuke Aoki.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Taira, J., Umei, T., Inoue, K. et al. Improvement of the novel inhibitor for Mycobacterium enoyl-acyl carrier protein reductase (InhA): a structure–activity relationship study of KES4 assisted by in silico structure-based drug screening. J Antibiot 73, 372–381 (2020).

Download citation


Quick links